Policy
Nader Pourhassan, who led CytoDyn for nearly 10 years, was convicted in December 2024 of misleading investors regarding the biotech’s investigational COVID-19 and HIV drug, which artificially inflated its share price.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
First Approved Treatment for XLH in Canada that Targets the Underlying Cause of this Rare, Hereditary, Lifelong Disease
Acquires Orphan Drug Designation for betahistine for the treatment of obesity associated with Prader-Willi syndrome (PWS)
Positive interim analysis demonstrated proof-of-biology and proof-of-concept for BIIB067
Meeting with FDA confirmed that studies previously conducted using first generation ProSavin® may be considered part of a single development program with AXO-Lenti-PD
Medtronic is notifying customers worldwide of a voluntary field corrective action for its Puritan Bennett(TM) 980 (PB980) ventilator series. Medtronic initiated this field action on September 19, 2018.
Ingenza is pleased to announce that Syngenta is exercising its commercial licensing option for a technology that enables the development of innovative crop protection products.
he Ministry of Health and Prevention recently met with a Chinese delegation to discuss mutually beneficial cooperation in the use of technological innovations such as artificial intelligence (AI) in the health care sector.
Noted biotech investor G. Steven Burrill will only spend 30 months in jail for his involvement in wire fraud and tax evasion. Burrill pleaded guilty to the charges last year and, at the time, faced up to 30 years in prison. Now, he will serve less than one-tenth of that amount.
Researchers who focus on HIV vaccines are caught in the middle of a political battle over funding of fetal stem cell research.
The FDA is often publishing draft guidelines and asking for expert feedback on that guidance. It’s been a busy week in this regard, with several areas of healthcare and drug development and manufacturing being covered by the agency. Here’s a look.